What To Know
- He is extensively involved in stroke and neuroendovascular research, with more than 500 peer-reviewed papers and multiple industry and NIH grants, including for a study on improving revascularization techniques in stroke.
- Brinjikji will provide MIVI with input and medical guidance across a wide spectrum of its activities, including original clinical research and studies, product design and development, and clinical and customer communications.
Dr Waleed Brinjikj is an internationally respected interventional neuroradiologist based in Rochester, Minn. He is extensively involved in stroke and neuroendovascular research, with more than 500 peer-reviewed papers and multiple industry and NIH grants, including for a study on improving revascularization techniques in stroke.
Most recently, Dr. Brinjikji was chief medical officer of Marblehead Medical, a Minnesota-based stroke company. He trained at top North American institutions including the University of Toronto and the Mayo Clinic.
As medical director, Dr. Brinjikji will provide MIVI with input and medical guidance across a wide spectrum of its activities, including original clinical research and studies, product design and development, and clinical and customer communications.
“We’re looking forward to Dr. Brinjikji joining our team at this exciting time,” said Bob Colloton, MIVI CEO. “His insights and experience will be invaluable as we continue to achieve our clinical and commercial milestones for our flagship products the Q Aspiration Catheter and DAISe Thrombectomy Device, and identify new business and development opportunities.”
Dr. Brinjikji commented, “The MIVI team shares my passion for improving the lives of patients who suffer an acute ischemic stroke. I am looking forward to representing MIVI in the neurointerventional community and contributing to the advancement of novel technologies that advance stroke treatment.”
The Q Aspiration Catheter delivers unprecedented aspiration power by optimizing luminal radius and length. It is CE-marked in Europe and under Investigational Device Exemption in the United States, where it is currently commercially available for distal access. The DAISe Thrombectomy Device is designed to reduce distal embolization and improve patient outcomes. It is currently available for investigational use only.